Efficacy of Surgery and Further Treatment of Progressive Glioblastoma

World Neurosurgery
Christoph Michael WoernleLuca Regli

Abstract

Treatment options for patients with glioblastoma at progression have remained controversial, and selection criteria for the appropriate type of intervention remain poorly defined. The objectives were to determine which factors favor the decision for second surgery and which factors are associated with overall survival (OS) and to evaluate the National Institutes of Health (NIH) recurrent glioblastoma scale. The scale includes tumor involvement of eloquent brain regions, functional status, and tumor volume. A retrospective single-center analysis of patients with newly diagnosed glioblastoma undergoing initial surgery between January 2007 and December 2011 was performed. Patients were separated into two groups: those with versus those without second resection surgery at disease progression. OS was compared using the multiple logistic regression model, Cox proportional hazard regression, and Kaplan-Meier survival analysis. The data of 98 patients were statistically analyzed. Among the patients, 58 had initial surgery only (age 61.27 years; median OS [mOS] 14.81 months) and 40 underwent second surgery at disease progression (age 55 years; mOS 18.86 months). Age was the only predictor for repeated surgery (P = 0.012; odds ratio 0.94...Continue Reading

References

Nov 1, 1987·Neurosurgery·G R HarshC B Wilson
Mar 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W RoaP Forsyth
Feb 1, 2005·Surgical Neurology·Andreas M StarkUlrike Blömer
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathryn A CarsonEdward G Shaw
Jul 10, 2007·Acta Neuropathologica·David N LouisPaul Kleihues
May 23, 2008·Neurosurgery·Nader Sanai, Mitchel S Berger
Jun 24, 2008·British Journal of Neurosurgery·Giuseppe M V BarbagalloAndrew R Brodbelt
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Teri N KreislHoward A Fine
Jul 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John K ParkPeter McL Black
May 20, 2011·Current Treatment Options in Oncology·James FinkMarc C Chamberlain
Oct 23, 2012·Journal of Neurosurgery·Kaisorn L ChaichanaAlfredo Quiñones-Hinojosa
Nov 9, 2012·Neuro-oncology·Michael WellerWolfgang Wick

❮ Previous
Next ❯

Citations

Jan 27, 2016·Clinical Neurology and Neurosurgery·Nicola MontemurroRiccardo Vannozzi
Feb 3, 2016·Critical Reviews in Oncology/hematology·Katharina SeystahlMichael Weller
Jul 11, 2016·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Joshua D BurksMichael E Sughrue
Oct 23, 2015·Clinical Neuroradiology·T HuberJ S Bauer
Jun 16, 2017·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Christoph StraubeStephanie E Combs
May 16, 2018·Angiogenesis·Daniel A P GuerraAlexander Birbrair
Jan 20, 2018·Journal of Neuro-oncology·Jonathan RickManish K Aghi
Feb 18, 2016·Future Oncology·Alba A BrandesEnrico Franceschi
Nov 22, 2017·Journal of Neuro-oncology·Etienne AudureauUNKNOWN Club de Neuro-Oncologie of the Société Française de Neurochirurgie
Dec 22, 2019·International Journal of Molecular Sciences·Nayuta HigaKazunori Arita
Jun 14, 2020·Neurosurgical Review·David BotrosDebraj Mukherjee
Mar 15, 2019·British Journal of Cancer·Muhammad KamilKazunori Arita

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.